REG - Proteome Sciences - Change of Registered Office

Proteome SciencesAnnouncement

26/05/2022 09:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220526:nRSZ9136Ma&default-theme=true

RNS Number : 9136M  Proteome Sciences PLC  26 May 2022

26 May 2022

 

 

 

 

 

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Change of Registered Office

 

The directors of Proteome Sciences announce that the Company's registered
office address has changed to Coveham House, Downside Bridge Road, Cobham,
Surrey KT11 3EP with immediate effect.

 

 

 

 

For further information:

 

 Proteome Sciences plc

 Dr Mariola Soehngen, Chief Executive Officer &
 Dr Ian Pike, Chief Scientific Officer  Tel: +44 (0)20 7043 2116

 Allenby Capital Limited (AIM Nominated Adviser & Broker)
 John Depasquale / Jeremy Porter        Tel: +44 (0) 20 3328 5656

 

 

About Proteome Sciences plc. (www.proteomics.com (http://www.proteomics.com/)
)

 

Proteome Sciences plc is a specialist provider of contract proteomics services
to enable drug discovery, development and biomarker identification, and
employs proprietary workflows for the optimum analysis of tissues, cells and
body fluids.  SysQuant® and TMT®MS2 are unbiased methods for identifying
and contextualising new targets and defining mechanisms of biological
activity, while analysis using Super-Depletion and TMTcalibrator™ provides
access to over 8,500 circulating plasma proteins for the discovery of
disease-related biomarkers. Targeted assay development using mass spectrometry
delivers high sensitivity, interference-free biomarker analyses in situations
where standard ELISA assays are not available.

 

The Company has its headquarters in London, UK, with laboratory facilities in
Frankfurt, Germany.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CROFIFITELIRFIF